Efficacy and Safety of Human Papillomavirus Vaccine for Primary Prevention of Cervical Cancer: A Review of Evidence From Phase III Trials and National Programs
This article, published in the South Asian Journal of Cancer, discusses the justification of human papillomavirus (HPV) vaccination in the backdrop of the natural history of cervical cancer, the mechanism of action of the vaccines, and efficacy and safety data from Phase 3 randomized controlled trials. Although HPV vaccines have been widely introduced in most medium- and high-income countries following endorsement from national and international advisory bodies, HPV vaccine introduction has been challenging in the following ways. It is the first vaccine developed to prevent cancer, the vaccine is gender-specific, and it targets adolescent females who are difficult to reach by any health intervention programs.
Author: Basu P, Banerjee D, Singh P, Bhattacharya C, Biswas J
» Visit web page (English)
(Located at www.ncbi.nlm.nih.gov)
Citation: Basu P, Banerjee D, Singh P, Bhattacharya C, Biswas J. Efficacy and Safety of Human Papillomavirus Vaccine for Primary Prevention of Cervical Cancer: A Review of Evidence From Phase III Trials and National Programs. South Asian Journal of Cancer. 2013;2(4):187-192.
Resource types: Peer-reviewed journal
Diseases/vaccines: Human papillomavirus (HPV)